Teladoc Q3 revenue up 8% to $660.2M; adjusted EBITDA surges 73% to $88.8M

Teladoc Health, Inc.

2023-Q3 EPS reported -$1.17 revenue$1,941,888,000

Net loss narrowed to $57.1M ($0.35/sh) from $73.5M ($0.45/sh) a year ago; adjusted EBITDA $88.8M.
Integrated Care revenue +9% to $374.4M; BetterHelp revenue +8% to $285.8M.
Operating cash flow $105.6M, free cash flow $68.0M; strong cash generation.
Q4 guidance: rev $658-683M, adj EBITDA $107-117M; FY23 rev $2.60-2.625B, adj EBITDA $320-330M.
CEO announces comprehensive operational review to drive efficiency and improve business performance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Teladoc Health, Inc. reported the third quarter of 2023 results: revenue $660.2 million, net income $57.1 million, EPS $0.35 per share.

Period: the third quarter of 2023
Revenue: $660.2 million
Net income: $57.1 million
EPS: $0.35 per share
Result: reported results

Exact text from the filing

Teladoc Health Reports Third Quarter 2023 Results • Third quarter 2023 revenue grows 8% year-over-year to $660.2 million • Third quarter 2023 operating cash flow of $105.6 million; free cash flow of $68.0 million • Third quarter 2023 net loss of $57.1 million, or $0.35 per share • Third quarter 2023 adjusted EBITDA of $88.8 million, up 73% year-over-year

View on SEC.gov

Browse all earnings releases →

Teladoc Health, Inc. filing history →

Source: SEC EDGAR

accession 0001477449-23-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.